AVEO Pharmaceuticals announced preliminary data from the exploratory, randomized Phase 2 study comparing the combination of ficlatuzumab and gefitinib (Iressa; AstraZeneca Pharmaceuticals), to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer (NSCLC), a population with a high prevalence of EGFR sensitizing mutations (SM+).
SIGN IN WITH ONE OF YOUR SOCIAL ACCOUNTS
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH ONE OF YOUR SOCIAL ACCOUNTS
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a password reset link.
ENTER NEW PASSWORD